Franklin Biotechnology Discovery Fund Class C (FBTDX)

Fund Assets	804.12M
Expense Ratio	1.80%
Min. Investment	$1,000
Turnover	n/a
Dividend (ttm)	11.76
Dividend Yield	11.52%
Dividend Growth	n/a
Payout Frequency	n/a
Ex-Dividend Date	Dec 20, 2024

Previous Close	100.75
YTD Return	-6.03%
1-Year Return	2.01%
5-Year Return	0.41%
52-Week Low	n/a
52-Week High	n/a
Beta (5Y)	n/a
Holdings	92
Inception Date	Mar 4, 2014

About FBTDX

The Franklin Biotechnology Discovery Fund Class C (FBTDX) seeks to provide capital appreciation. Under normal market conditions, the Fund predominantly invests in equity securities and invests at least 80% of its net assets in securities of biotechnology companies(at least 50% of its earnings derived from biotechnology activities) and discovery research firms.

• Category: Health
• Performance Rating: Below Average
• Risk Rating: Above Average
• Stock Exchange: NASDAQ
• Ticker Symbol: FBTDX
• Share Class: Class C
• Index: NASDAQ Biotechnology CR

Performance

FBTDX had a total return of 2.01% in the past year, including dividends. Since the fund's inception, the average annual return has been 3.04%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
FRBRX	Class R6	0.69%
FTDZX	Advisor Class	0.80%
FBDIX	Class A	1.05%

Top 10 Holdings

50.13% of assets

Name	Symbol	Weight
Amgen Inc.	AMGN	8.11%
Gilead Sciences, Inc.	GILD	7.82%
Vertex Pharmaceuticals Incorporated	VRTX	7.75%
Regeneron Pharmaceuticals, Inc.	REGN	5.50%
Ascendis Pharma A/S	ASND	4.42%
Jazz Pharmaceuticals plc	JAZZ	4.10%
argenx SE	ARGX	3.80%
PTC Therapeutics, Inc.	PTCT	3.13%
Merus N.V.	MRUS	2.93%
Neurocrine Biosciences, Inc.	NBIX	2.57%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 20, 2024	$11.7607	Dec 20, 2024
Dec 15, 2021	$16.6721	Dec 15, 2021
Dec 15, 2020	$10.3921	Dec 15, 2020
Dec 16, 2019	$14.1643	Dec 18, 2019
Dec 17, 2018	$4.5496	Dec 19, 2018
Dec 15, 2017	$3.5969	Dec 19, 2017